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Abstract Females are more susceptible to pulmonary arterial hypertension than 
males, although the reasons remain unclear. The hypoglycaemic drug, metformin, is 
reported to have multiple actions, including the inhibition of aromatase and 
stimulation of AMPK. Inhibition of aromatase using anastrazole is protective in 
experimental pulmonary hypertension but whether metformin attenuates pulmonary 
hypertension through this mechanism remains unknown. We investigated whether 
metformin affected aromatase activity and if it could reduce the development of 
pulmonary hypertension in the sugen 5416/hypoxic rat model. We also investigated 
its influence on proliferation in human pulmonary arterial smooth muscle cells. 
Metformin reversed right ventricular systolic pressure, right ventricular hypertrophy 
and decreased pulmonary vascular remodelling in the rat. Furthermore, metformin 
increased rat lung AMPK signalling, decreased lung and circulating estrogen levels, 
levels of aromatase, the estrogen metabolizing enzyme; cytochrome P450 1B1 and 
its transcription factor; the aryl hydrocarbon receptor. In human pulmonary arterial 
smooth muscle cells, metformin decreased proliferation and decreased estrogen 
synthesis by decreasing aromatase activity through the PII promoter site of 
Cyp19a1. Thus, we report for the first time that metformin can reverse pulmonary 
hypertension through inhibition of aromatase and estrogen synthesis in a manner 
likely to be mediated by AMPK.  
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Introduction 
Human pulmonary arterial hypertension (PAH) is a progressive disease of the 
pulmonary vasculature, which often leads to right heart failure. PAH is characterised 
by elevated pulmonary pressure (>25mmHg at rest), vascular remodeling and 
occlusive pulmonary vascular lesions. Although survival rates are improving slowly; 
there remains an unacceptably poor survival rate.1 
Females are more susceptible to PAH than males, as indicated in, for example, the 
REVEAL registry where around 80% of the patients registered were female.2,3 
However male patients, have a poorer survival rate than females, implicating sex 
hormones in both PAH susceptibility and survival.4 
Consequently the role of estrogens in PAH has been accumulating significant 
interest.5-8 There is an estrogen ‘paradox’ however as whilst exogenous estrogen 
may be protective against experimental pulmonary hypertension (PH) and right 
ventricular (RV) hypertrophy in rodent models,9-12 endogenous estrogen is causative 
in female animal models.13-17 Estrogen is synthesised from testosterone through the 
enzyme aromatase and inhibition of aromatase attenuates experimental PH but only 
in females.17  Estrogen can be metabolised through the cytochrome p450 1b1 
(CYP1B1) enzyme to form the mitogenic 16α-hydroxyestrone (16α-OHE1), a 
metabolite established to be pathogenic in PH.16 Furthermore, single nucleotide 
polymorphisms of CYP1B1 have been recently identified to be  associated with PH 
and indicated to play a key role in sexual dimorphism in RV failure.18 One 
transcription factor for CYP1B1 is the aryl hydrocarbon receptor (AhR), suppression 
of which has been shown to be anti-proliferative (protective) in PH.19   
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Metformin is a well-established drug for use in type 2 diabetes mellitus (T2DM)20-21 
and has been demonstrated to activate AMP-activated protein kinase AMPK in many 
tissues, although AMPK does not underlie the hypoglycaemic actions of metformin.22 
AMPK is a ubiquitously expressed serine/threonine protein kinase, which plays a 
critical role in cellular and organ metabolism.23,24 In breast cancer and polycystic 
ovarian syndrome (PCOS) the therapeutic effects of metformin involves the 
enhancement of the AMPK pathway and inhibition of the nuclear translocation of 
CREB-regulated transcription coactivator 2 (CRTC2). CRTC2 (a downstream target 
of AMPK) can bind to the PII promoter site of the aromatase (Cyp19a1) gene and 
regulate aromatase activity and expression.25  In breast cancer and PCOS, it is 
hypothesised that an additional therapeutic mechanism of metformin may be 
aromatase inhibition.26,27 Metformin has been shown to reverse the development of 
experimental PH.28 Here we examine the hypothesis that metformin may reverse 
experimental PH through inhibition of aromatase in a manner mediated by AMPK 
activation. 
Sugen (SU5416) is an inhibitor of vascular endothelial growth factor (VEGF) R2 
receptors. A single dose of sugen combined with hypoxia followed by weeks of 
normoxia provides a refined model of PAH exhibiting high pulmonary pressures and 
occlusive pulmonary lesions (the sugen/hypoxic rat model ((hereafter termed 
SuHx)).29,30 As this is a gold-standard model for testing potential new therapies, we 
used this model to determine if any therapeutic effect of metformin was associated 
with aromatase inhibition in PH.  We have previously shown that aromatase 
inhibition was only effective in female hypoxic and SuHx rat models of PH, having no 
effect in male rats with PH.17 As we were specifically looking to identify the inhibitory 
action of metformin on aromatase, we therefore selected females for this study. We 
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further investigated the mechanism of action of metformin in human pulmonary 
arterial smooth muscle cells (hPASMC) from non-PAH and PAH female patients.  
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Materials and Methods 
Animals studies  
Wistar Kyoto adult (nine weeks) female (Harlan, UK) rats were divided into three 
groups (n=12 per group), control (with no PH induced), vehicle dosed (0.9% (w/v) 
NaCl in distilled water for 21 days) and metformin dosed. The latter two groups 
received a single dose of Sugen-5416 (Novartis, UK) (20mg/kg), before being placed 
in a hypobaric chamber (atmospheric pressure 550 mbar) for two weeks and then 
placed in normal room pressure (1013 mbar) for three weeks whilst PH developed. 
Animals were then dosed, daily (oral gavage) with vehicle or with metformin 
(100mg/kg (dissolved in 0.9% (w/v) NaCl) p.o., od for a further 21 days). Full details 
of subsequent haemodynamic measurements (right ventricular systolic pressure 
(RVSP), right ventricular hypertrophy (RVH) can be found in the online supplement.  
Immunohistochemistry 
Immunohistochemistry was carried out as described previously and further details 
are described in the online supplement.16,17 
Protein Analysis 
Protein analysis was carried out by western blotting as described previously and in 
the online supplement.16,17 
Gene expression analysis 
mRNA was measured  by RT-PCR  as described previously, reagent/probe details 
are described in the online supplement. 16,17  
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Estrogen Immunoassay 
Levels of 17β estradiol were determined by competitive immunoassay in lung 
samples and plasma from female rats from each group, full details are in the online 
supplement.  
Human Pulmonary Arterial cells  
Human PASMCs were provided by Professor Nicholas W. Morrell (University of 
Cambridge) and cultured as described previously and in the online supplement.  
Aromatase activity Assay (tritiated water-release assay) 
Aromatase activity was assessed using a modification of methods described 
previously31 and in the online supplement.  
Statistics 
Data is represented as the group mean ± SEM. Data was analyzed by either a 
student’s t test (where there were only two groups), or a one-way ANOVA followed 
by a Bonferroni’s Post Hoc test.  
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Results  
Metformin reduces the pulmonary hypertension phenotype in the SuHx female 
rat model and reverses proliferation of hPASMCs  
SuHx vehicle-dosed rats developed increased RVSP and RVH and this was 
normalised by metformin treatment (Figures 1A, B). A majority of the pulmonary 
arteries within vehicle animals were remodeled and this was significantly reduced by 
metformin treatment (Figure 1C). Only in vehicle-treated animals were occluded 
lesions found (Figure 1D) (similar to human disease) suggesting severe PH. No 
occluded lesions were found in any of the metformin dosed animals (Figure 1D). 
Remodeling and occluded lesions were confirmed by immunohistochemistry (Figure 
1E, 1F, 1G) 
No differences were found in mean systolic arterial pressure (mSAP), glucose levels, 
cardiac output or heart rate (Figure S1A, 1B, 1C and 1D). Increased proliferation 
(indicated by PCNA) was found in vehicle exposed SuHx animals, particularly in 
occluded lesions and PCNA levels were decreased in metformin-treated rats (Figure 
1H), illustrating the anti-proliferative effects of metformin within the SuHx  model.  
In the SuHx PH rat model, metformin decreases estrogen levels and estrogen 
metabolism and enhances the lung AMPK pathway 
To determine if metformin was affecting CRTC2, aromatase and subsequent 
estrogen synthesis, we first measured lung gene expression of CRTC2. Metformin 
caused a significant decrease in CRTC2 mRNA levels compared with vehicle-dosed 
and control animals (Figure 2A). An increase in aromatase protein levels was found 
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in the lungs of SuHx animals, metformin reversed this increase in lung aromatase 
protein (Figure 2B).  Plasma estrogen levels were increased in the SuHx vehicle 
group (Figure 2C). Metformin treatment decreased both circulating and local lung 
estrogen levels consistent with the decreased aromatase levels (Figure 2C, 2D). 
CYP1B1 protein levels in lung were significantly increased in the SuHx control group 
and this was decreased by metformin treatment (Figure 2E). Immunohistochemistry 
indicated lung aromatase, CYP1B1 and AhR levels (Figure 2F) were increased in 
vehicle exposed SuHx animals, particularly in occluded lesions; expression of each 
protein was decreased in metformin exposed rats. Metformin caused a significant 
increase in lung pAMPK (Figure 2G) levels as well as downstream phosphorylation 
of ACC (Figure 2H), indicative of an increase in AMPK activity. Protein levels of the 
AMPK kinase-LKB1 (upstream of AMPK) in the rat lung were unchanged by vehicle 
or metformin treatment in comparison to control animals (S2A), indicating metformin 
directly activates AMPK (without altering levels of the upstream kinase).  
Metformin is anti-proliferative in hPASMCs. Exposure of female hPASMCs to 
metformin decreases CRTC2 gene expression, decreases PII promoter activity 
of the CYP19A1 (aromatase) gene and decreases aromatase activity in female 
hPASMCs.  
Metformin decreased serum-induced proliferation in hPASMCs in both non-PAH 
(~58%) (Figure 3A) and PAH patient cells (~70%) (Figure 3B). Inhibiting aromatase 
with anastrozole also decreased PASMC proliferation in non-PAH (~56%) and PAH 
patient cells (~66%) (Figure 3A, 3B). All results were confirmed by studying BrdU 
incorporation (S3A, 3B). The AMPK activator AICAR also decreased proliferation in 
patient cells (~59%) (Figure 3B). In hPASMCs, metformin treatment decreased 
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CRTC2 gene expression (41%) in non-PAH cells and 61% in PAH cells (Figure 3C). 
Metformin, anastrazole and AICAR all significantly reduced activity of the PII 
promoter region of the aromatase gene in non-PAH hPASMC cells transfected with a 
luciferase reporter gene (Figure 3D). Aromatase activity in non-PAH hPASMCs was 
decreased by metformin, AICAR and anastrozole treatments (Figure 3E). 
 
Exposure of female hPASMCs to metformin decreases downstream estrogen 
metabolism and increases pAMPK levels  
AhR levels were increased in PAH hPASMCs in comparison to non-PAH hPASMCs 
(Figure 4A). Metformin significantly reduced AhR levels in PAH hPASMCs (Figure 
4A). CYP1B1 levels were increased in PAH hPASMCs in comparison to non-PAH 
hPASMCs (Figure 4B) this was also decreased by metformin in PAH hPASMCs 
(Figure 4B). Metformin treatment of non-PAH hPASMCs increased pAMPK (Figure 
4C) and downstream pACC (Figure 4D). LKB1 expression (upstream of AMPK) was 
unchanged (S2B). Incubation of hPASMCs with AICAR or the aromatase inhibitor 
anastrozole for 24h did not activate the AMPK pathway as assessed by pAMPK and 
pACC (Figure 4C, 4D respectively).However, we found AICAR to activate the AMPK 
pathway in hPASMCs, earlier at a 2 hour time point (S4).  
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Discussion  
We report metformin can reduce PH in the rat SuHx model as well as proliferation in 
hPASMCs and describe a novel mechanism of action via aromatase inhibition. 
Metformin reversed the elevation in both RVSP and RVH in the SuHx rat, reduced 
pulmonary vascular remodeling and completely deterred the formation of occluded 
pulmonary vascular lesions suggesting metformin inhibited the disease from 
reaching severity. Metformin had no effect on systemic blood pressure, plasma 
glucose levels and no effect on cardiac output and heart rate, demonstrating that the 
observed effects are pulmonary specific and independent of glycaemia. Metformin 
reduced proliferation in hPASMCs consistent with the anti-proliferative effects of 
metformin reported in other cell types, (MCF7s and glioma cells in cancers).32,33 We 
considered possible mechanisms by which metformin could be exerting its 
therapeutic and anti-proliferative effects.  
For the first time we report metformin inhibits estrogen synthesis in the female SuHx 
rat and aromatase activity within hPASMCs. We have reported previously, 
aromatase expression is elevated in lungs from SuHx rats and inhibiting aromatase 
using anastrozole reversed PH in the female SuHx model.17 In the current study, 
metformin reduced elevated aromatase expression to normal in the lungs and 
importantly, it reduced both lung and plasma estrogen levels in the SuHx rat. This 
confirms aromatase inhibition is protective in PH, furthermore the aromatase 
decreasing effects of metformin did not have any adverse effect on the right ventricle 
in these studies. Indeed, metformin is the first line of treatment for thousands of 
people with diabetes and there are no reports of right ventricular dysfunction 
following chronic treatment.22 The inhibition of aromatase by metformin is of key 
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interest as women are more susceptible to PAH and estrogens and or estrogen 
metabolites may therefore be pathogenic in this disease. Additionally, genetic 
variation of aromatase and estrogen signaling is also involved in other related 
pathogenicities such as portopulmonary hypertension (PPHTN)34. Recently it has 
been shown that iPAH (idiopathic pulmonary arterial hypertension) male patients 
have elevated circulating estrogen levels,18 associated with poorer 6 minute walk 
distance and RV function and consequently it is worth considering anastrazole or 
metformin (given its effects on aromatase) may well be effective in male patients and 
post-menopausal women at select doses. This data may indicate limitations with 
regards to differences seen in human vs animal studies as we have previously 
shown that male mice with PH have very low circulating estrogen levels and 
estrogen levels in male Su/Hx rats were undetectable unlike the human male 
patients.17 
We show metformin can both inhibit aromatase activity and decrease the activity of a 
reporter gene containing the PII promoter of the aromatase gene. It is well 
established that CRTC2 can bind to the PII promoter site of aromatase 27  and we 
show metformin reduced CRTC2 gene expression in rat lung as well as hPASMCs. 
Phosphorylated CRTC2 stops nuclear translocation, although we were unable to 
measure phosphorylation, our studies demonstrate metformin can alter CRTC2 
mRNA expression, which may offer a novel means by which metformin can regulate 
CRTC2 . These results may reflect reduced CRTC2 activity, as suggested by our 
results of decreased PII driven expression and as supported by the work of others 35 
indicating metformin activated AMPK inactivates CRTC2 to decrease aromatase 
expression. Interestingly, CRTC2 mRNA was not found to be increased in our SuHx 
vehicle rat group however the same group had significantly increased aromatase 
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expression.  It should be noted that protein levels might not reflect mRNA levels; we 
were unable, however, to measure CRTC2 protein due to lack of an efficient 
antibody. We have shown previously that animals with PH (both mouse hypoxic and 
rat sugen model), have increased aromatase expression in remodeled pulmonary 
arteries. In addition, female lungs from the animal PH models and female hPASMCs 
express increased levels of aromatase protein compared with male17 in comparison 
to respective controls. The increased aromatase we report did not correlate with 
increased local estrogen. There is increased metabolism of estrogen in the SuHx rat 
model 16 and hence whilst there may be more synthesis of estrogen, it will be 
metabolised quickly to metabolites such as 16α-OHE1 16 hence levels of actual 
estrogen may not necessarily be expected to mirror levels of aromatase.  
Here we demonstrated an increase in whole lung aromatase in the SuHx rat [Sugen 
plus 3 weeks hypoxia plus 6 weeks normoxia] rat whereas in our previous study this 
did not reach significance in the SuHx rat lung [Sugen plus 2 weeks hypoxia plus 2 
weeks normoxia].17 This most likely reflects the different protocols adopted between 
the two studies.  
CYP1B1 is a major enzyme in estrogen metabolism, converting estradiol to pro-
mitogenic estrogen metabolites.36 CYP1B1 plays a role in the development of PAH16 
and metformin has been shown to inhibit CYP1B1 activity in breast cancer cells.37,38 
We demonstrate CYP1B1 to be increased in PAH hPASMCs in comparison to 
control cells (as reported previously16) and that metformin treatment was beneficial in 
reducing CYP1B1 expression in both the SuHx rat model as well as in hPASMCs.  
AhR is a transcription factor known to regulate CYP1B1.39, 40  To the best of our 
knowledge, only one study has reported a role for AhR in PH, whereby inhibition of 
HYPE201607353D 
14 
 
TGF-β1 using baicalin led to a decrease in hPASMC proliferation through a decrease 
in AhR.19  AhR antagonism is considered a promising mode of treatment and 
preventive target for diseases, such as gastric and breast cancer and nitric oxide 
dependent vasculature diseases.41,42 We found elevated expression of AhR in 
vehicle SuHx rats, particularly in occluded lesions and this was reversed by 
metformin. For the first time, we demonstrate increased AhR expression in 
hPASMCs from PAH patients in comparison to non-PAH patients and we show that 
metformin can reduce AhR expression in both rat lung and hPASMCs.  
We found pAMPK levels were not changed in the lungs of female SuHx rats in 
comparison to control, but metformin treatment induced an increase in pAMPK and 
also the downstream substrate, pACC, suggesting the pathway is upregulated and 
may be protective in PH, as described previously.28 Metformin also increased 
phosphorylation of AMPK and ACC in hPASMCs. Interestingly hPASMC treatment 
with the AMPK activator, AICAR did not have the same effect at the 24 hour time 
point. This may reflect the mechanism by which AICAR activates AMPK, whereby 
AICAR is transported into the cell and phosphorylated to form ZMP.43 The 
accumulated ZMP binds directly to the γ subunit of AMPK, mimicking AMP and 
stimulating AMPK phosphorylation. Initial activation of AMPK would be sufficient to 
retard the cell cycle and thereby reduce proliferation, in the same way that 
stimulating cells with growth factors only transiently increases proximal signalling 
pathways whereas increased proliferation, which relies on the time taken to undergo 
cytokinesis remains increased long after those signalling pathways have returned to 
basal levels. The timescale of our experiments may, therefore, have exceeded the 
time course of ZMP accumulation and AMPK activation. Metformin inhibits 
mitochondrial ATP synthesis, reducing the cellular energy charge, which activates 
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AMPK.44 This process may well continue for 24 hours, such that the AMPK pathway 
may still be activated after 24 hours in response to metformin but not AICAR. 
Subsequently we demonstrated AICAR activates AMPK in hPASMCs at a much 
earlier time point of 2 hours (SF4).   
Enhancement of the AMPK pathway is involved in regulation of several different 
pathways; therefore the therapeutic effects of metformin could involve additional 
mechanisms. For example, AMPK activation can affect the cyclooxygenase pathway 
as well as the mTOR pathway, both known to be dysregulated in PAH.45,46 Moreover, 
metformin targets the mitochondria of cells and this is where steroidogenesis takes 
places. Emerging data indicates metformin can dampen the entire steroidogenesis 
pathway,43,47 and activated AMPK is reported to inhibit HMG CoA reductase (which 
regulates cholesterol synthesis) thus leading to a decrease in steroidogenesis.48  
It is possible that all the therapeutic effects of metformin could be driven via its ability 
to increase AMPK, and this work is supported by other studies which indicate AMPK 
to be protective in PH28, however, conflict exists, whereby it has also been shown 
that a decrease in AMPK may be protective against PH.49  
 We previously showed that aromatase inhibition was only effective in female 
hypoxic and SuHx rat models of PH, having no effect in male rats with PH.17 As we 
were specifically looking to identify the additional inhibitory action of metformin on 
aromatase, we therefore selected female rats. In addition, metformin has already 
been shown to reverse PH in male hypoxic and monocrotaline PH rats via other 
mechanisms of action,28 therefore it would most certainly have had an effect in males 
in our model via other mechanisms.  This would not, however, have determined any 
additional effect on aromatase activity. We were unable to measure different 
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estrogen metabolites in the lung tissue from our experimental rats as there are no 
available assays with sufficient sensitivity. We and others have however provided 
evidence that increased CYP1B1 may contribute to PAH pathology via increased 
accumulation of mitogenic metabolites such as 16α-OHE1.16, 50,51  
In summary, we have demonstrated metformin to be protective in PH in the rat SuHx 
model and anti-proliferative in hPASMCs. We show aromatase expression and 
activity as well as estrogen metabolism (via AhR/CYP1B1 axis inhibition) in both rat 
and human models were down regulated by metformin. We report that metformin 
increases pAMPK, which can affect CRTC2 gene expression, and aromatase PII 
promoter activity. This mechanism is summarized in S5. As metformin is already in 
widespread use in the clinic and well tolerated by patients, our study denotes this 
drug to be beneficial in experimental PH and merits further investigation as a therapy 
for PAH. The study also suggests a role for AhR in PH which is worthy of further 
investigation. 
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Perspectives: 
The precise role of estrogen, its formation and its metabolites, in pulmonary arterial 
hypertension requires to be fully understood in order to understand why females are 
more susceptible to the disease. Our studies show metformin can inhibit aromatase 
expression and activity to decrease estrogen but also its metabolism and this is 
beneficial in reversing the disease phenotype in females. In pulmonary hypertension, 
this is a novel mechanism which is highly relevant given the role of estrogen 
metabolites and estrogen synthesis in the disease. Furthermore, metformin is 
already in widespread use as an anti-cancer drug and well tolerated by patients and 
thus suggests a practical therapy for females with this devastating disease.  
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 Novelty and significance  
What Is New?  
• We have identified that metformin can reverse pulmonary hypertension in 
females through inhibition of aromatase and decrease of estrogen and its 
metabolites, this mechanism has not been reported in PH previously.  
• We report, for the first time, that AhR is increased in female patient pulmonary 
arterial smooth muscle cells in comparison to non-patient pulmonary arterial 
smooth muscle cells and metformin can decrease AhR.  
What is relevant?  
• The ability of metformin to affect steroidogenesis to reverse PH in females is 
extremely relevant as a gender bias exists in this disease.  
• Given the importance of AhR in mediating toxicity, it is very relevant to note 
that metformin can decrease levels of AhR and that AhR may be modulated 
by AMPK in this disease.  
Summary  
Our study shows that metformin may provide an alternative therapy for females with 
pulmonary arterial hypertension through its target of AMPK and estrogen synthesis 
and metabolism.  
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Figure Legends  
Figure 1. Metformin treatment attenuates SuHx induced pulmonary hypertension in 
female rats and is anti-proliferative. (A) Right ventricular systolic pressure (RVSP, 
n=8-10 per group), (B) Right ventricular hypertrophy (RVH, n=10-13 per group) and 
(C) percentage of remodeled arteries in lungs without treatment (control) and SuHx 
treatment with vehicle or metformin, n=7-12. (D) Percentage of occluded vessels 
found in each group, n=7. (E) Representative images showing elastic laminae 
stained indicative of extent of remodelling of arteries. (F) Representative image of 
occluded vessel (only found in vehicle exposed animals) stained with anti-von 
Willebrand factor. (G) Representative image of complex vascular lesions (similar to 
human disease) (only found in vehicle exposed SuHx animals) stained with anti-von 
Willebrand. (H) Representative images and immunoratio quantification of 
proliferation (stained by PCNA) within the female rat lung. Solid scale bar represents 
20µm, dashed scale bar represents 50µm. Data represents mean ±SEM. * P<0.05, 
**P<0.01 ***P<0.001 as indicated, determined by one way ANOVA followed by 
Bonferroni post test. 
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Figure 2. Metformin decreases estrogen levels and metabolism and enhances the 
lung AMPK pathway in female rat lung  
Effect of Su/Hx treatment with or without metformin on (A) relative gene expression 
levels of CRTC2 (n= 6-9 per group), (B) aromatase protein levels (representative 
immunoblot and quantification of n= 4-8 per group shown), (C) circulating estrogen 
levels, (D) Local estrogen levels within lung, n=8-10, (E) CYP1B1 protein levels 
(representative immunoblot and quantification of n= 4-8 per group shown), (F) 
Localisation and expression of aromatase (brown staining), CYP1B1 (red staining) 
and AhR (pink staining) in lung vessels (representative images shown), (G) AMPK 
phosphorylation levels and (H) ACC phosphorylation levels. Representative 
immunoblots and quantification of n=7-8 per group are shown. 
Scale bar represents 20µm. C=Control (no sugen/hypoxic treatment), V=Vehicle 
(sugen/hypoxic treatment), M=Metformin (sugen/hypoxic treatment with metformin). 
Data is displayed as a mean ±SEM. * P<0.05, **P<0.01 ***P<0.001 as indicated, 
determined by one way ANOVA followed by Bonferroni post test. 
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Figure 3. Metformin is anti-proliferative in hPASMCs, through an aromatase and 
AMPK axis and exposure of female hPASMCs to metformin decreases CRTC2 gene 
expression, aromatase activity through the PII promoter region of cyp19a1.  (A) 
Normalised cell counts of non-PAH (A) and PAH (B) female hPASMC depicting 
proliferation due to 10% (v/v) serum, and anti-proliferative effects of 24 hour 
treatment with either metformin, AICAR or anastrozole (in the presence of 10% 
serum), n=4-5 different  cell lines, each count repeated in triplicate. (C) Relative gene 
expression levels of CRTC2 in non-PAH and PAH hPASMCs exposed to metformin 
for 24 hours, n=4 per group. (D) Luciferase activity of non-PAH cells transfected with 
PII promoter site of cyp19a1 gene construct and exposed to treatment. (E)  
Aromatase activity in non-PAH hPASMCs exposed to metformin, AICAR or 
anastrozole for 24 hours, repeated in 2 different non-PAH cell lines. Data is 
displayed as mean ±SEM. * P<0.05, **P<0.01 ***P<0.001 as indicated, analysed by 
one way ANOVA followed by Bonferroni post test. 
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Figure 4. Exposure of hPASMC to metformin decreases AhR, CYP1B1 and 
enhances the AMPK pathway. (A) Representative immunoblot and quantification, 
showing basal levels of AhR protein expression in female non-PAH and PAH 
hPASMCs and effect of metformin on AHR expression n=3-5 per group. (B) 
Representative immunoblot and quantification, showing basal levels of CYP1B1 
protein expression in female non-PAH and PAH hPASMCs and effect of metformin, 
n=3-6 per group. Phosphorylated AMPK (C) and phosphorylated ACC (D) after 24 
hours of exposure to the indicated agents. N=2-3 different cell lines per group.  
C=Control, M=Metformin, AC=AICAR, A=Anastrozole. Data is displayed as mean 
±SEM. * P<0.05, **P<0.01 ***P<0.001 as indicated, determined by unpaired t-test 
when comparing only two groups all others analysed by one way ANOVA followed 
by Bonferroni post test.  
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Materials and Methods 
Ethics 
All experimental procedures were carried out in accordance with the United Kingdom 
Animal Procedures Act (1986) and with the "Guide for the Care and Use of 
Laboratory Animals" published by the US National Institutes of Health (NIH 
publication No. 85-23, revised 1996), and ethical approval was also granted by the 
University of Glasgow Ethics Committee. Rodents were housed in a 12-hour light 
dark cycle with access to food and water ad libitum. Experimental procedures using 
hPASMCs conform to the principles outlined in the Declaration of Helsinki. 
 
Animal studies  
In vivo Hemodynamic Measurements 
Wistar Kyoto female rats, aged 9 weeks, were purchased from Harlan, UK. The 
animals were housed in a 12-hour light-dark cycle with access to food and water ad 
libitum. Animals were housed together to promote synchronisation of their estrous 
cycles two weeks prior to the study. In order to ensure animals were synchronising 
together, a blunt, shortened tip of a Pasteur pipette was placed at the vaginal orifice. 
One drop of PBS was gently expelled into the vagina and aspirated back before 
being transferred to a microscope slide. Smears were examined microscopically and 
classified as to the stage of the cycle.  
In vivo Hemodynamic Measurements 
Animals were anaesthetically induced in 3% (v/v) isoflurane and then maintained at 
1.5-2% (v/v) isoflurane supplemented with a constant flow of 5% (v/v) oxygen. Under 
anaesthesia, prior to hemodynamic measurements being taken, a small volume (2-3 
drops) of blood was removed from the tail vein for glucose measurements, using an 
Accu-Chek mobile glucose monitor and strips (https://www.accu-chek.co.uk/gb/). 
There was no requirement for analgesic or tranquilizing drugs in this study.  
Haemodynamic measurements were done in a blinded fashion. Right ventricular 
systolic pressure (RVSP) measurements were taken using a Polyimide Mikro-Tip 
pressure volume catheter (ADI instruments spr-869NR); 12.5cm effective length, 
with a pressure sensor (2F) and four electrodes, with a pressure sensor centered 
between E2 and E3. The catheter was used as per the manufacturer’s instructions 
and attached to corresponding software (LabChart Pro). This catheter was inserted 
into the jugular vein and guided into the right ventricle of the heart to measure RVSP. 
After RVSP was determined, the carotid vein was isolated and the same catheter 
used to determine mean systemic arterial pressures. This pressure- volume (PV) 
loop system also generated the cardiac output (CO) data. Blood was collected 
immediately in a heparinised syringe for plasma analysis.  
 
Right ventricular hypertrophy and tissue harvest 
Immediately following hemodynamic assessment, the heart and lungs were flushed 
with ice-cold PBS at a low pressure to clear peripheral blood cells. The right lung 
was excised for molecular analysis. The left lung was inflated with 10% (v/v) neutral 
buffered formalin (NBF) and left in NBF solution for 48 hours before paraffin 
processing and embedding for immunohistological analysis.  
Right ventricular hypertrophy (RVH) was assessed by the Fulton Index (dry weight of 
the right ventricle/(dry weight of the left ventricle + septum).1  
 
Immunohistochemistry 
Sections (3μm) were cut and stained using Millers elastin/picro Sirius Red for 
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identification of vascular thickening, characterized by an increase in the vessel wall 
diameter in more than 50% of the arterial wall. The total number of remodelled 
vessels was expressed over the total number of vessels present in a lung section as 
assessed by a blinded investigator. In order to determine the presence of occluded 
vessels, sections were stained with rabbit anti-von wilibrand factor (Dako, A0082 
1:1000). The total number of occluded vessels were counted in lung sections of each 
animal by a blinded investigator. Additional sections were stained using anti-
aromatase (Abexxa abx13974 1:200), anti-CYP1B1 (Abcam, Ab32649 1:500), anti-
AHR (Abcam Ab153744 1:200) and anti-PCNA (Abcam Ab2426 1:1000) antibodies. 
An anti-rabbit IgG secondary antibody was used for each primary antibody (Vector 
Laboratories IMMpress kit) and protein immuno-localisation was visualized with the 
DAB substrate kit (Vector labs UK (sk-4600). PCNA staining was quantified using 
ImunoRatio software (jvsmicroscope.uta.fi/immunoratio/).  
 
Human Pulmonary Arterial cells  
Human PASMCs were provided by Professor Nicholas W. Morrell (University of 
Cambridge). Female hPASMCs were explanted from the distal pulmonary 
microvasculature from subjects with either no reported presence of PAH, referred to 
as non-PAH cells or from patients with reported PAH. Patient characteristics are 
shown in Table 1. Assays were performed between passages 4 and 7. Cells were 
seeded in 24-well plates (for cell proliferation or luciferase assay) and 6 well plates 
(for protein, RNA or aromatase activity analysis) at a density of 10,000 cells per cm2. 
Cells were grown to ~60% confluency and then synchronized by serum-deprivation 
(0.2% (v/v) charcoal-stripped FBS) in phenol-red free DMEM (Invitrogen, UK) for 24 
hours for all experiments apart from the aromatase activity protocol, in which cells 
were treated without serum deprivation. Proliferation studies were carried out in 
charcoal-stripped media using cell counting and BrdU incorporation studies.  
 
Charcoal-Stripped Fetal Bovine Serum  
Fetal bovine serum (FBS; Sera Labs, UK) was charcoal-stripped twice to remove 
estrogens. Dextran-coated charcoal (1% (w/v), Sigma-Aldrich, UK) in FBS was 
agitated gently overnight at 4ºC. Samples were centrifuged at 1811 g at 4ºC for 30 
minutes. The stripped serum was decanted and filtered through a 0.22µm filter. 
 
Effect of Metformin on PASMC proliferation  
Cell counts: 
PASMCs plated in 24 -well plates were used for these studies. Following serum 
deprivation, cells were replenished with fresh phenol-red free DMEM (Invitrogen, UK) 
supplemented with 2% (v/v) or 10% (v/v) FBS and metformin (2 mM), AICAR (3 
mM), anastrazole (1 μM), 17β-estradiol, TMS (2,3’,4,5’-tetramethoxystilbene) or AhR 
antagonist CH223191 ( 1-Methyl-N-[2-methyl-4-[2-(2-methylphenyl)diazenyl]phenyl-
1H-pyrazole-5-carboxamide) (10μM). Cells were incubated for 24 hours before cell 
proliferation was assessed, in a blinded fashion, by cell counting using a 
haemocytometer.  
 
BrdU incorporation assay:  
Cells were seeded in 96 well plates at a density of 2000 cells per well. Cells were 
grown to ~60% confluency and then synchronized by serum-deprivation for 24 hours. 
Cells were then treated for a further 24 hours in medium supplemented with 2% (v/v) 
or 10% (v/v) FBS and metformin (2 mM), AICAR (3 mM) or anastrazole (1 μM). 
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BrdU incorporation was measured in each well as per the manufacturer’s instructions 
(Millipore UK). Absorbance in each well was measured using a spectrophotometric 
plate reader at dual wavelengths of 450-540 nm 
 
Aromatase activity Assay (tritiated water-release assay) 
Female non-PAH hPASMCs were plated in six-well plates and grown to 60% 
confluency. Cells were cultured in medium supplemented with 2% serum and 2mM 
metformin, 3mM AICAR or 1µM Anastrazole. Aromatase activity in these cells was 
measured using the 3H2O release assay in the presence or absence of 30 μM 
[3H]androst-4-ene-3, 17-dione (NET926001MC, PerkinElmer) for 18 hours. Media 
was removed and placed in 30% TCA and 100% chloroform and left overnight for 
steroid extraction.  The upper phase was removed, added to 5% (w/v) charcoal 
dextran and centrifuged at 3000g for 30 minutes at 4°C. The upper phase was 
removed and radioactivity determined using a liquid scintillation counter. Activity was 
corrected for by protein concentration.  
 
Plasmid hPASMC transfection studies  
Non-PAH cells were transfected with the CYP19A1 p11-516 reporter construct 
(generated and provided by Dr Kristy Brown of Monash University) using 
lipofectamine (as per the manufacturer’s instructions). Eight hours post transfection; 
cells were stimulated with experimental agents for 24 hours. Luciferase reporter 
assay was carried out using a Promega Luciferase Assay system E1500 as 
instructed by the manufacturer. Further details are described in the online 
supplement.  
Female non-PAH hPASMCs were plated in six-well plates and grown to 60% 
confluency. Cells were synchronized by serum-deprivation for 24 hours (0.1% (w/v) 
charcoal stripped serum). PII promoter plasmid was provided by Dr Kristy Brown of 
Monash University. Cells were transfected with 400ng of plasmid in lipofectamine 
(Invitrogen) as per manufacturer’s instruction. Briefly, cells were washed twice with 
500µl optimem (Invitrogen) before addition of 500µl of 10% (v/v) fetal bovine serum 
DMEM containing no antibiotics to each well. Next, 100µl of transfection mix 
(containing 400 ng of plasmid) was added to each well and cells transferred back to 
the humidified cell culture chamber. After 8 hours the transfection media was 
removed and replaced with medium containing 10% (v/v) charcoal-stripped FBS in 
the presence or absence of metformin (2mM), AICAR (3 mM) or anastrazole (1μM).  
Cells were transferred back to a humidified cell culture chamber at 37°C and 
incubated for 24 hours. To measure the luciferase activity, a luciferase reporter 
assay was carried out using a Promega Luciferase Assay system E1500 according 
to the manufacturer’s instructions. Briefly, growth media was aspirated and each well 
washed with PBS. PBS was aspirated, and 100µl of 1x passive lysis buffer (PLB) 
was added into each well. The 6 well plates were transferred to -80°C for 5 minutes 
to flash freeze the lysates. Cells were placed on ice, on a shaker for 10 minutes and 
each well was scraped into a microcentrifuge tube and centrifuged at 12,000rpm for 
5 minutes at 4°C. Thereafter 20µl of supernatant was transferred into a single well of 
a white 96-well plate (in duplicate). 100µl of Luciferase Assay Reagent (LAR) was 
added per well and light reaction measured using LUMIstar OPTIMA microplate 
reader (BMG Labtech).  
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Protein Analysis 
Whole lung rat samples were homogenized and hPASMCs were lysed in ice-cold 
0.1% (w/v) lauryl maltoside (Abcam, UK) solution in PBS (v/v).  Protein 
concentrations were determined on a nanodrop (ND-1000 spectrophotometer 
(Thermo Scientific, UK). 20µg of protein was loaded for hPASMCs and whole lung 
homogenates, for protein identification by SDS-PAGE and immunoblotting. Protein 
expression was quantitated in immunoblots probed with rabbit anti-aromatase 
(Abbexa, abx13974 1:200), anti-CYP1B1 (Abcam ab32649 1:200) anti-phospho-
AMPK Thr172 (Cell Signaling, #2535, 1:500), anti-phospho-ACC Ser79 (Cell 
signaling #3361 1:800) , anti-LKB1 (Cell Signalling #3047 1:1000), anti-AhR (Abcam 
ab153744 1:100), total-AMPK (Cell signaling 2532 1:1000) and total-ACC (Cell 
signaling 3676 1:1000).  antibodies by overnight incubation at 4°C, subsequently 
incubated with anti-rabbit secondary antibodies and immunoblots developed using 
Pierce™ ECL Western Blotting Substrate (Life Technologies)and normalized to 
GAPDH (abcam, ab8264, UK; 0.2µg/ml).  Densitometrical analysis was performed 
using TotalLab TL100 software 
 
Gene expression analysis 
 For quantitative analysis of gene expression by qRT-PCR, total RNA was extracted 
from rat lung samples from the different treatment groups (control, vehicle and 
metformin) and hPASMCs treated in the presence or absence of either 2% or 10% 
charcoal stripped serum supplemented with 2 mM metformin, 3 mM AICAR or 1 µM 
anastrazole, using an RNeasy Micro Kit with on-column DNase digestion (Qiagen, 
UK).  
Random hexamer primed cDNA was prepared using the Applied Biosystems 
TaqmanTM RT kit (Applied Biosystems, CA). Quantitative real time PCR (qRT-PCR) 
was performed on the ABI Prism Sequence Detection System (Applied Biosystems). 
Expression of CRTC2 mRNA was determined using the Life Technologies Universal 
Probe Library (Roche Applied Sciences, Burgess Hill, UK) using primers listed 
in Table 2 below. The expression level of each gene was corrected using GAPDH 
expression as internal control. All samples were performed in duplicate. CT values 
were determined with Opticon2 software.  
 
 
Estrogen Immunoassay 
The levels of 17β estradiol were determined by competitive immunoassay in lung 
samples and plasma from female rats from each group, (control, vehicle and 
metformin). 400µg of protein was loaded and assayed in duplicate as per the 
manufacturer’s instructions (Demeditec, USA). The plate was read at a wavelength 
of 405nm for kinetic and end point measurements (SpectraMax M2 plate reader, 
Molecular Devices, California, USA). Protein samples from lung tissue were made in 
1% LM buffer. We contacted Demeditec to discuss that we had detected estradiol 
levels in these samples which were within the standard curve range/detection limit. 
They stated that although the kit was designed for serum and plasma, there is no 
technical reason as to why estradiol would not be detected in the protein sample 
from tissue.  
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Table S1. hPASMC patient information 
Available patient 
information  Age  Condition  Treatment 
Female Non-PAH  
64 Emphysema (mild) aspirin 
 
59 Squamous cell carcinoma 
aspirin, 
simvastatin, 
bisoprolol, 
ramipril, 
metalazine, 
quinine sulphate, 
loperamide 
 
71 Adenocarcinoma  
 
70 Left lower lobectomy  
    
Female PAH  
24 Idiopathic PAH 
 
30 
R899X, presented at 23 
year old. Systolic PAP 90, 
diastolic PAP 30, mean 
PAP 46, mixed venous 
STATS 66.3%, NYHA II, 
6MWD 400m 
IV prostanoids, 
warfarin, 
zopliclone, 
mebeverine, 
frusemide by 
transplantation 
  
Unknown  IPAH   
 
 
Table S2: Assay Id numbers for qRT-PCR. 
 
  Gapdh  Crtc2 
Rat  Rn01775763_g1 Rn01455374_m1 
Human  Hs02758991_g1 Hs01064500_m1 
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Supplementary Figures 
 
 
Figure S1. mSAP, glucose levels, cardiac output and heart rate are not significantly 
altered in female Sugen/hypoxic rats exposed to metformin. (A) mSAP was 
unchanged between the group, this was also found for glucose levels (B), cardiac 
output (C) and heart rate (D). Glucose levels were measured at day 7, 14 and 21 
(data shown for day 21) of treatment in each group and no significant difference in 
blood glucose levels, taken from tail vein, was found.  n=6-13 per group.  Data was 
analysed by one way ANOVA followed by Bonferroni post test. 
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A 
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Figure S2. Representative immunoblots and quantification relative to GAPDH of 
LKB1 (A) in whole lung from control (no sugen/hypoxic) and sugen/hypoxic animals 
without (vehicle) or with metformin treatment. n=4-8 per group. C= Control, 
V=Vehicle, M=Metformin. (B) Representative immunoblots and quantification, 
showing effects of 24h incubation with metformin, AICAR or anastrozole on LKB1 in 
female non-PAH hPAMSCs (n=2-3 different cell lines per group). C=Control, 
M=Metformin, AC=AICAR, A=Anastrozole. Data is displayed as a mean ±SEM 
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Figure S3. Non PAH female hPASMCs (A) and PAH female hPASMCs (B) were 
incubated in 2% (v/v) FBS or 10% (v/v) FBS in the presence or absence of the 
indicated agents for 24h and BrdU incorporation assessed. n=2 cell lines/group, 
repeated seven times per group. Data is displayed as mean ±SEM. * P<0.05, 
**P<0.01 ***P<0.001 as indicated, determined by one way ANOVA followed by 
Bonferroni post test. 
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Figure S4. Non-PAH female hPASMCs (A) were incubated in 2% (v/v) FBS in the 
presence (or absence–time point 0) of AICAR (3 mM) for either 2, 4, 6 or 10 hours. 
The activation of AMPK was assessed by measuring pAMPK protein expression 
over tAMPK protein expression. n=3 cell lines/group. Data is displayed as mean 
±SEM. * P<0.05, **P<0.01 ***P<0.001 as indicated, determined by one way ANOVA 
followed by Bonferroni post test. 
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Figure S5. Schematic illustrating the proposed pathway of mechanism of metformin 
action in experimental PH. Metformin increases pAMPK and one effect of this is to 
cause a decrease in CRTC2. CRTC2 binding to the PII promoter of aromatase is 
decreased, which means less estrogen is synthesised from testosterone by 
aromatase. Metformin treatment decreased AhR expression. AhR is a transcription 
factor for the estrogen metabolising enzyme CYP1B1. CYP1B1 expression was 
decreased by metformin, possibly due to the decrease in its transcription factor. We 
have previously suggested decreased CYP1B1 activity can protect against PH by 
decreasing accumulation of estrogen metabolites.2, 3  
 
 
 
 
